In this issue, an article by Waring et al. provides a meta-analysis of the effects of apo-lipo-
protein E (APOE) genotype on the beneficial effect of acetyl-cholinesterase inhibitors …

The thesis of the article by Martorana et al.[1]“Beyond the cholinergic hypothesis. Do current
drugs work in Alzheimer's disease?” is that despite the observations showing an association …

Decades of research have produced no effective method to prevent, delay the onset, or slow
the progression of Alzheimer's disease (AD). In contrast to these failures …

Alzheimer's disease (AD) was first described and diagnosed by Dr. Alois Alzheimer in 1906
(Hippius and Neundorfer, Dialogues Clin Neurosc 5: 101–108, 2003). According to World …

Alzheimer′ s disease (AD) is a neurodegenerative disease, one of whose major
pathological hallmarks is the accumulation of amyloid plaques comprised of aggregated β …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and
cognitive loss, and represents the leading cause of dementia in elderly people. Besides the …

Background: Genetic heterogeneity in amnestic mild cognitively impaired (aMCI) subjects
could lead to variations in progression rates and response to cholinomimetic agents …

Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative
disorder, causes cognitive decline and has a devastating effect on the quality of life. AD …

Although the hallmarks of neurodegeneration in Alzheimer's brains are well known, one of
the current difficulties is related to the lack of solid evidence about the ultimate factors that …

Current studies suggest that apolipoprotein E (apoE) genotype influences the rate of
progression in Alzheimer's disease (AD), with patients carrying the e4 allele progressing …